Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study DOI Creative Commons
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, María Piñeiro‐Lamas

et al.

European Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 71, P. 96 - 108

Published: April 4, 2023

The World Health Organization has proposed that a search be made for alternatives to vaccines the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought assess: impact previous SSRI antidepressants on severity COVID-19 (risk hospitalisation, admission an intensive care unit [ICU], mortality), its influence susceptibility SARS-CoV-2 progression severe COVID-19. We conducted population-based multiple case-control in region north-west Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) 95%CIs calculated using multilevel logistic regression. collected data total 86,602 subjects: 3060 cases PCR+, 26,757 non-hospitalised PCR+ 56,785 controls (without PCR+). Citalopram displayed statistically significant decrease risk hospitalisation (aOR=0.70; 95% CI 0.49-0.99, p = 0.049) (aOR=0.64; 0.43-0.96, 0.032). Paroxetine was associated mortality (aOR=0.34; 0.12 - 0.94, 0.039). No class effect observed SSRIs overall, nor any other found remaining SSRIs. results this large-scale, real-world indicate that, citalopram, could candidate drug repurposed as preventive aimed at reducing patients' progressing stages disease.

Language: Английский

Antidepressants for COVID-19: A systematic review DOI
Wei Zheng, Heli Sun, Hong Cai

et al.

Journal of Affective Disorders, Journal Year: 2022, Volume and Issue: 307, P. 108 - 114

Published: March 23, 2022

Language: Английский

Citations

23
Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2 DOI Creative Commons
Bradley A. Fritz, Nicolas Hoertel, Eric J. Lenze

et al.

Translational Psychiatry, Journal Year: 2022, Volume and Issue: 12(1)

Published: Aug. 22, 2022

Antidepressants have previously been associated with better outcomes in patients hospitalized COVID-19, but their effect on clinical deterioration among ambulatory has not fully explored. The objective of this study was to assess whether antidepressant exposure reduced emergency department (ED) or hospital visits SARS-CoV-2 infection. This retrospective cohort included adult (N = 25 034) a positive test performed non-hospital setting. Logistic regression analyses tested associations between home use medications and composite outcome ED visitation admission within 30 days. Secondary exposures individual antidepressants functional inhibition acid sphingomyelinase (FIASMA) activity. Patients were less likely experience the primary compared without (adjusted odds ratio [aOR] 0.89, 95% CI 0.79-0.99, p 0.04). association only observed daily doses at least 20 mg fluoxetine-equivalent (aOR 0.87, 0.77-0.99, 0.04), lower than 0.94, 0.80-1.11, 0.48). In exploratory secondary analyses, incidence also selective serotonin reuptake inhibitors 0.75-0.99, bupropion 0.70, 0.55-0.90, 0.005), FIASMA drugs 0.03). Antidepressant patients, dose-dependent manner. These data support model antidepressants' effects against COVID-19.

Language: Английский

Citations

23
Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities DOI Creative Commons
Mohammad Shah Alam

Heliyon, Journal Year: 2023, Volume and Issue: 9(2), P. e13285 - e13285

Published: Jan. 31, 2023

The Omicron, the latest variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in November 2021 Botswana, South Africa. Compared to other variants SARS-CoV-2, Omicron is most highly mutated, with 50 mutations throughout genome, which are spike (S) protein. These may help evade host immunity against vaccine. Epidemiological studies suggest that infectious and spreads rapidly, but causes significantly less disease than wild‐type strain SARS-CoV-2. With increased transmissibility a higher rate re-infection, has now become dominant worldwide predicted be able vaccine-induced immunity. Several clinical using plasma samples from individuals receiving two doses US Food Drugs Administration (FDA)-approved COVID-19 vaccines have shown reduced humoral immune response infection, T cell-mediated well preserved. In fact, protects disease, thus caused by remains mild. this review, I surveyed current status mechanisms context escape vaccines. also discuss potential implications therapeutic opportunities independent SARS-CoV-2 variants, including Omicron. A better understanding responses variant-independent interventions include potent antiviral, antioxidant, anti-cytokine activities pave way reducing Omicron-related complications, severity, mortality. Collectively, these insights point research gaps will aid development new-generation antiviral drugs combat its sublineages, or upcoming new

Language: Английский

Citations

16
Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial DOI Creative Commons
Ramin Hamidi Farahani, Ali Ajam,

Alireza Ranjbar Naeini

et al.

BMC Infectious Diseases, Journal Year: 2023, Volume and Issue: 23(1)

Published: March 31, 2023

Abstract Background Shortly after the Coronavirus disease 2019 (COVID-19) pandemic, a considerable number of recovered patients reported persisting symptoms, especially neuropsychological manifestations, which were later named post-COVID syndrome (PCS). Immune dysregulation was suggested as one main mechanisms for PCS. Fluvoxamine, selective serotonin reuptake inhibitor (SSRI) that is mostly used to treat depression, anxiety disorders, and obsessive–compulsive disorder, has been an anti-COVID drug due its anti-inflammatory effects, mainly through sigma-1 receptor. Therefore, we aimed evaluate fluvoxamine's effect on PCS neuropsychiatric symptoms. Method In this double-blind randomized clinical trial, included confirmed mild moderate COVID-19 outpatients using polymerase chain reaction (PCR) by infectious specialist. The presence severe symptoms evaluated specialist dyspnea, SpO2 < 94% room air, PaO2/FiO2 300 mm Hg, respiratory rate > 30 breaths/min, lung infiltrates 50%. Then performed permuted block randomization assigned 1:1 into two groups either receive fluvoxamine 100 mg tablet or placebo daily 10 days. Eligible 12 weeks fatigue, primary, other secondary outcomes. Results We screened total 486 from March June 2022. After weeks, 42 receiving 43 Placebo Patients had mean age 38.5 ± 14.1 48% them women. Fatigue significantly lower in group ( p -value 0.026). No significant differences observed Conclusion concluded taking during active can reduce chance fatigue but advantage not Further studies are necessary confirm these preliminary results.

Language: Английский

Citations

14
Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study DOI Creative Commons
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, María Piñeiro‐Lamas

et al.

European Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 71, P. 96 - 108

Published: April 4, 2023

The World Health Organization has proposed that a search be made for alternatives to vaccines the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought assess: impact previous SSRI antidepressants on severity COVID-19 (risk hospitalisation, admission an intensive care unit [ICU], mortality), its influence susceptibility SARS-CoV-2 progression severe COVID-19. We conducted population-based multiple case-control in region north-west Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) 95%CIs calculated using multilevel logistic regression. collected data total 86,602 subjects: 3060 cases PCR+, 26,757 non-hospitalised PCR+ 56,785 controls (without PCR+). Citalopram displayed statistically significant decrease risk hospitalisation (aOR=0.70; 95% CI 0.49-0.99, p = 0.049) (aOR=0.64; 0.43-0.96, 0.032). Paroxetine was associated mortality (aOR=0.34; 0.12 - 0.94, 0.039). No class effect observed SSRIs overall, nor any other found remaining SSRIs. results this large-scale, real-world indicate that, citalopram, could candidate drug repurposed as preventive aimed at reducing patients' progressing stages disease.

Language: Английский

Citations

13